May 23, 2007
In order to provide faster identification of bloodstream pathogens, bioMérieux has signed an exclusive US distribution agreement for AdvanDx Inc’s PNA FISH rapid diagnostic tests.
AdvanDx, Inc.’s molecular-based tests provide rapid species identification of bacteria and yeast from positive blood cultures in less than three hours. This allows clinicians to make faster and more relevant therapy decisions that can improve antibiotic management, reduce hospital mortality, and reduce costs associated with bloodstream infections.
Based on the peptide nucleic acid fluorescence in situ hybridization (PNA FISH) technology, tests that are part of this agreement enable rapid identification of Staphylococcus aureus, Candida albicans, and Enterococcus faecalis, and other species from positive blood cultures.
